Supplementary Data — Adintrevimab for COVID-19: real-time meta-analysis of 2 studies

@CovidAnalysis, October 2026, Version 1V1

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Adintrevimab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ison (DB RCT)33%0.67 · 0.11–3.98death2/1,0013/1,001EVADE PrEP Ison (DB RCT)50%0.50 · 0.13–1.99death3/1,0016/1,001EVADE PrEP Ison (DB RCT)84%0.16 · 0.02–1.34death1/7526/728EVADE PrEP Ison (DB RCT)84%0.16 · 0.02–1.34hosp.1/7526/728EVADE PrEP Ison (DB RCT)70%0.30 · 0.16–0.56symp. case12/75239/728EVADE PrEP Ison (DB RCT)67%0.33 · 0.01–8.15death0/2401/241EVADE PEP Ison (DB RCT)80%0.20 · 0.01–4.15death0/2402/241EVADE PEP Ison (DB RCT)80%0.20 · 0.01–4.15hosp.0/1752/176EVADE PEP Ison (DB RCT)75%0.25 · 0.07–0.88symp. case3/17512/176EVADE PEP

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Adintrevimab
reduces riskAdintrevimab
increases risk →

Fig. S1. All outcomes.